癌症合并急性冠脉综合征患者死亡、出血与缺血事件风险预测模型研究
该评分用于预测癌症合并急性冠脉综合征患者6个月全因死亡、大出血和缺血事件,外部验证显示具有良好的区分度和校准度。研究提示该工具可辅助平衡治疗获益与风险。
要点
- ONCO-ACS评分可同时预测癌症合并ACS患者6个月死亡、大出血及缺血事件风险。
- 评分纳入肿瘤类型、癌症诊断时间、转移状态、年龄、血红蛋白、心率、eGFR、BMI、Killip分级、心脏骤停及6个月内大出血史。
- 大多数癌症合并ACS患者根据现行指南可能适合有创管理及氯吡格雷长期双联抗血小板治疗。
核心结论
- ONCO-ACS评分是一个经过验证的实用工具,可预测癌症合并急性冠脉综合征患者的死亡、出血和缺血风险。
- 联合评估竞争性结局风险有助于平衡治疗获益与危害。
研究设计与样本
- 采用竞争风险框架和6个月预测时限,在英格兰数据中开发机器学习模型,并在英格兰中部、瑞典和瑞士的外部数据集中验证。
主要发现
- ONCO-ACS校准良好,决策曲线分析提示具有较好的临床效用。
关键数值与推荐
- 评分变量包括:肿瘤类型、癌症诊断时间、转移性疾病、年龄、血红蛋白、心率、估算肾小球滤过率、BMI、Killip分级、心脏骤停及6个月内大出血。
临床怎么用
- ONCO-ACS评分可用于癌症合并急性冠脉综合征患者的个体化风险评估。
- 将ONCO-ACS应用于现行指南提示,大多数癌症合并急性冠脉综合征患者符合有创管理和氯吡格雷长期双联抗血小板治疗的条件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate assessment of mortality, bleeding, and atherothrombotic risk in patients with cancer and acute coronary syndrome could inform novel personalised treatment strategies, but no standardised tools for this purpose exist. We aimed to develop and validate a clinically applicable risk score for mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome. METHODS: In this model development and validation study, we obtained data for 1 017 759 patients who presented with acute coronary syndrome in England, UK (n=815 170; 36 771 with cancer), Sweden (n=194 059; 10 262 with cancer), and Switzerland (n=8530; 203 with cancer) between Jan 1, 2004, and Aug 8, 2023. Machine learning models were developed to predict all-cause mortality, major bleeding events, and ischaemic events, defined as a composite of cardiovascular death, myocardial infarction, and ischaemic stroke, in patients with cancer and acute coronary syndrome from England in a competing risks framework with a prediction horizon of 6 months. Final models (the ONCO-ACS score) were externally validated in geographically distinct held out datasets from the English Midlands, Sweden, and Switzerland. FINDINGS: Patients with cancer and with acute coronary syndrome were characterised by high rates of mortality (cumulative incidence 27·8% [95% CI 27·3-28·3]), major bleeding (7·3% [7·0-7·5]), and ischaemic events (16·1% [15·7-16·4]) and had a distinct risk profile. The ONCO-ACS score was informed by a single set of variables: tumour type, time since cancer diagnosis, metastatic disease, age, haemoglobin, heart rate, estimated glomerular filtration rate, BMI, Killip class, cardiac arrest, and major bleed within 6 months. Accounting for traditional and cancer-related risk factors, ONCO-ACS showed a time-dependent area under the receiver operating characteristic curve (tAUC) at 6 months of 0·84 (0·83-0·85) for all-cause mortality, 0·70 (0·68-0·73) for major bleeding, and 0·79 (0·78-0·81) for ischaemic events on internal validation. On external validation, ONCO-ACS achieved similar performance for all-cause mortality (tAUC at 6 months 0·84 [0·82-0·85] for the English Midlands, 0·80 [0·79-0·82] for Sweden, and 0·83 [0·76-0·91] for Switzerland), major bleeding events (0·70 [0·67-0·74] for the English Midlands, 0·67 [0·65-0·70] for Sweden, and 0·74 [0·57-0·91] for Switzerland), and ischaemic events (0·76 [0·74-0·78] for the English Midlands, 0·70 [0·69-0·72] for Sweden, and 0·73 [0·61-0·86] for Switzerland). ONCO-ACS was well calibrated and decision curve analyses suggested favourable clinical utility. Applying ONCO-ACS to current guidelines suggests that most patients with cancer and acute coronary syndrome qualify for invasive management and long dual antiplatelet therapy using clopidogrel. INTERPRETATION: The ONCO-ACS score provides a validated practical tool for predicting mortality, bleeding, and ischaemic risk in patients with cancer and acute coronary syndrome. Combined assessment of competing outcome risks could facilitate balancing treatment benefits and harms. FUNDING: British Heart Foundation, Cancer Research UK, Swiss Heart Foundation, University of Zurich Foundation, Kurt-Senta-Herrmann Foundation, Theodor-Ida-Herzog-Egli Foundation, Foundation for Cardiovascular Research-Zurich Heart House, Swedish ALF Research Funds.
引用
- Wenzl, Ow, Velders, et al. Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study. Lancet. 2026. PMID: 41620233. doi:10.1016/S0140-6736(25)02020-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。